Skip to main content

Table 2 Tumor response of the investigated patients with advanced esophageal squamous cell carcinoma as determined based on CT scans

From: Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial

Response

Treatment groups

Irinotecan plus S-1 [cases (%)]

S-1 monotherapy [cases (%)]

Total

61

62

CR

1 (1.6)

0 (0.0)

PR

14 (22.9)

6 (9.7)

SD

20 (32.8)

16 (25.8)

PD

14 (23.0)

26 (41.9)

Not assessable

12 (19.7)

14 (22.6)

  1. CT computed tomography, CR complete response, PR partial response, SD stable disease, PD progressive disease